Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective

Direct-acting antivirals (DAAs) have been a breakthrough therapeutic innovation in the treatment of chronic hepatitis C virus (HCV) with significantly improved efficacy, safety, and tolerability. To evaluate the cost-effectiveness of treating patients with HCV with DAAs compared with pre-DAAs or no...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of managed care & specialty pharmacy 2022-10, Vol.28 (10), p.1138-1148
Hauptverfasser:	Kaplan, David E, Serper, Marina, Kaushik, Ankita, Durkin, Claire, Raad, Angie, El-Moustaid, Fadoua, Smith, Nathaniel, Yehoshua, Alon
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral Agents - therapeutic use Cohort Studies Cost-Benefit Analysis Health Care Costs Hepatitis C, Chronic - drug therapy Humans Middle Aged United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!